$SGRY
Surgery Partners, Inc. Stock $sgry

$sgry Overview Financials Valuation SEC Filings Company Website

2017 Q4 Form 10-K Financial Statement

#000163883318000004 Filed on March 16, 2018

Income Statement

Concept	2017 Q4	2017 Q3
Revenue	$460.3M	$132.3M
YoY Change	50.44%	-53.21%
Cost Of Revenue	$338.7M	$102.9M
YoY Change	58.09%	-48.89%
Gross Profit	$121.6M	$29.33M
YoY Change	32.57%	-63.91%
Gross Profit Margin	26.42%	22.18%
Selling, General & Admin	$51.20M	$45.00M
YoY Change	28.64%	22.62%
% of Gross Profit	42.09%	153.41%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$18.40M	$3.330M
YoY Change	73.58%	-65.72%
% of Gross Profit	15.13%	11.35%
Operating Expenses	$69.70M	$120.3M
YoY Change	38.29%	-49.83%
Operating Profit	$51.94M	$11.93M
YoY Change	25.6%	-72.17%
Interest Expense	-$30.30M	-$15.88M
YoY Change	26.78%	-40.01%
% of Operating Profit	-58.33%	-133.18%
Other Income/Expense, Net	$25.50M	$17.40M
YoY Change	3542.86%	-524.39%
Pretax Income	$72.80M	-$2.859M
YoY Change	70.49%	-122.62%
Income Tax	$7.900M	-$211.0K
% Of Pretax Income	10.85%
Net Earnings	-$32.18M	-$9.140M
YoY Change	-290.82%	290.93%
Net Earnings / Revenue	-6.99%	-6.91%
Basic Earnings Per Share	-$0.83	-$0.57
Diluted Earnings Per Share	-$0.83	-$0.57
COMMON SHARES
Basic Shares Outstanding	48.77M shares	48.31M shares
Diluted Shares Outstanding		48.31M shares

Balance Sheet

Concept	2017 Q4	2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$174.9M	$199.7M
YoY Change	150.93%	261.78%
Cash & Equivalents	$174.9M	$214.2M
Short-Term Investments
Other Short-Term Assets	$38.50M	$15.48M
YoY Change	239.58%	49.04%
Inventory	$44.95M	$44.52M
Prepaid Expenses	$16.84M	$18.42M
Receivables	$288.0M	$271.1M
Other Receivables	$14.20M	$19.90M
Total Short-Term Assets	$563.2M	$573.7M
YoY Change	55.61%	74.51%
LONG-TERM ASSETS
Property, Plant & Equipment	$398.5M	$388.7M
YoY Change	95.06%	94.74%
Goodwill	$3.347B	$3.269B
YoY Change	115.2%	113.48%
Intangibles	$58.91M	$56.75M
YoY Change	22.67%	16.59%
Long-Term Investments	$77.70M	$67.50M
YoY Change	96.71%	71.32%
Other Assets	$48.67M	$19.13M
YoY Change	196.11%	38.34%
Total Long-Term Assets	$4.060B	$4.028B
YoY Change	108.93%	109.8%
TOTAL ASSETS
Total Short-Term Assets	$563.2M	$573.7M
Total Long-Term Assets	$4.060B	$4.028B
Total Assets	$4.623B	$4.602B
YoY Change	100.56%	104.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$84.71M	$73.25M
YoY Change	70.22%	64.78%
Accrued Expenses	$122.9M	$99.30M
YoY Change	73.1%	42.26%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$58.70M	$48.50M
YoY Change	111.15%	66.67%
Total Short-Term Liabilities	$303.0M	$275.0M
YoY Change	62.27%	53.94%
LONG-TERM LIABILITIES
Long-Term Debt	$2.252B	$2.562B
YoY Change	53.51%	81.58%
Other Long-Term Liabilities	$222.5M	$116.8M
YoY Change	191.72%	33.59%
Total Long-Term Liabilities	$222.5M	$116.8M
YoY Change	191.72%	33.59%
TOTAL LIABILITIES
Total Short-Term Liabilities	$303.0M	$275.0M
Total Long-Term Liabilities	$222.5M	$116.8M
Total Liabilities	$525.5M	$391.8M
YoY Change	99.81%	47.25%
SHAREHOLDERS EQUITY
Retained Earnings	-$41.32M	-$9.140M
YoY Change	-86.73%	-97.22%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$654.7M	$695.4M
YoY Change
Total Liabilities & Shareholders Equity	$4.623B	$4.602B
YoY Change	100.56%	104.64%

Cashflow Statement

Concept	2017 Q4	2017 Q3
OPERATING ACTIVITIES
Net Income	-$32.18M	-$9.140M
YoY Change	-290.82%	290.93%
Depreciation, Depletion And Amortization	$18.40M	$3.330M
YoY Change	73.58%	-65.72%
Cash From Operating Activities	$54.40M	-$1.222M
YoY Change	68.42%	-106.47%
INVESTING ACTIVITIES
Capital Expenditures	-$9.000M	$1.840M
YoY Change	-15.89%	-123.0%
Acquisitions		$1.163M
YoY Change
Other Investing Activities	-$26.90M	$0.00
YoY Change	37.24%	-100.0%
Cash From Investing Activities	-$35.80M	-$3.003M
YoY Change	18.15%	-85.7%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net		$3.609M
YoY Change
Cash From Financing Activities	-43.40M	-$10.28M
YoY Change	-447.2%	-277.24%
NET CHANGE
Cash From Operating Activities	54.40M	-$1.222M
Cash From Investing Activities	-35.80M	-$3.003M
Cash From Financing Activities	-43.40M	-$10.28M
Net Change In Cash	-24.80M	-$14.51M
YoY Change	-271.03%	-492.03%
FREE CASH FLOW
Cash From Operating Activities	$54.40M	-$1.222M
Capital Expenditures	-$9.000M	$1.840M
Free Cash Flow	$63.40M	-$3.062M
YoY Change	47.44%	-111.38%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017	dei	Amendment Flag AmendmentFlag	false
CY2017	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2017	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017	dei	Document Period End Date DocumentPeriodEndDate	2017-12-31
CY2017	dei	Document Type DocumentType	10-K
CY2017	dei	Entity Central Index Key EntityCentralIndexKey	0001638833
CY2018Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	48611578	shares
CY2017	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2017	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2017Q2	dei	Entity Public Float EntityPublicFloat	484100000	USD
CY2017	dei	Entity Registrant Name EntityRegistrantName	Surgery Partners, Inc.
CY2017	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2017	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2017Q4	sgry	Acquisition Escrow Liability Current AcquisitionEscrowLiabilityCurrent	3809000	USD
CY2017Q4	sgry	Acquisition Escrow Liability Noncurrent AcquisitionEscrowLiabilityNoncurrent	19600000	USD
CY2017Q4	sgry	Acquisition Escrow Receivable Current AcquisitionEscrowReceivableCurrent	3809000	USD
CY2017Q4	sgry	Acquisition Escrow Receivable Noncurrent AcquisitionEscrowReceivableNoncurrent	19600000	USD
	sgry	Amortizationof Unfavorable Lease Liability AmortizationofUnfavorableLeaseLiability	221000	USD
CY2015	sgry	Business Acquisition Numberof Physicians Addedto Network BusinessAcquisitionNumberofPhysiciansAddedtoNetwork	17	Physician
	sgry	Business Combination Contingent Acquisition Expense BusinessCombinationContingentAcquisitionExpense	1982000	USD
	sgry	Business Combination Contingent Compensation Expense BusinessCombinationContingentCompensationExpense	1900000	USD
	sgry	Business Combination Gain Loss On Acquisition Escrow BusinessCombinationGainLossOnAcquisitionEscrow	167000	USD
	sgry	Business Combination Integration Related Costs And Merger Costs BusinessCombinationIntegrationRelatedCostsAndMergerCosts	9330000	USD
	sgry	Business Combination Practice Acquisition Costs BusinessCombinationPracticeAcquisitionCosts	1800000	USD
	sgry	Debt Instrument Prepayment Penalty Amount DebtInstrumentPrepaymentPenaltyAmount	0	USD
	sgry	Deferred Income Tax Liability Gain On Amendment Of Liability DeferredIncomeTaxLiabilityGainOnAmendmentOfLiability	1100000	USD
CY2017Q4	sgry	Deferred Tax Asset Tax Receivable Agreement DeferredTaxAssetTaxReceivableAgreement	1042000	USD
CY2017Q4	sgry	Deferred Tax Assets Tax Deferred Expense Compensationand Benefits Compensated Absencesand Incentive Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationandBenefitsCompensatedAbsencesandIncentiveCompensation	2125000	USD
CY2017Q4	sgry	Deferred Tax Assets Tax Deferred Expense Deferred Financing Costs DeferredTaxAssetsTaxDeferredExpenseDeferredFinancingCosts	17004000	USD
CY2017Q4	sgry	Deferred Tax Liabilities Basis Differencesof Partnershipsand Joint Ventures DeferredTaxLiabilitiesBasisDifferencesofPartnershipsandJointVentures	2399000	USD
	sgry	Earnings Before Interest Taxes Depreciation And Amortization EarningsBeforeInterestTaxesDepreciationAndAmortization	78737000	USD
	sgry	Effective Income Tax Rate Reconciliation Nondeductible Mergerand Public Offering Costs Amount EffectiveIncomeTaxRateReconciliationNondeductibleMergerandPublicOfferingCostsAmount	2058000	USD
	sgry	Effective Income Tax Rate Reconciliation Tax Receivable Agreement Amount EffectiveIncomeTaxRateReconciliationTaxReceivableAgreementAmount	-7404000	USD
	sgry	Effective Income Tax Reconciliation Divestiture Amount EffectiveIncomeTaxReconciliationDivestitureAmount	-429000	USD
CY2017Q4	sgry	Estimated Insurance Recoveries Noncurrent EstimatedInsuranceRecoveriesNoncurrent	10018000	USD
	sgry	Finite Lived Intangible Asset Disposals FiniteLivedIntangibleAssetDisposals	140000	USD
	sgry	Gain Loss On Amendment To Tax Receivable Agreement GainLossOnAmendmentToTaxReceivableAgreement	1098000	USD
	sgry	Incentive Payments Recognizedfor Certain Hospitalsand Physician Practices That Demonstrate Meaningful Useof Certified Electronic Health Record Technology IncentivePaymentsRecognizedforCertainHospitalsandPhysicianPracticesThatDemonstrateMeaningfulUseofCertifiedElectronicHealthRecordTechnology	-45000	USD
	sgry	Increaseof Revenueas Resultof Changesin Estimatesto Thirdparty Settlements Relatedto Prior Years IncreaseofRevenueasResultofChangesinEstimatestoThirdpartySettlementsRelatedtoPriorYears	0	USD
	sgry	Intangible Assets Professional Recruitment Expense IntangibleAssetsProfessionalRecruitmentExpense	227000	USD
	sgry	Intereston Contingent Consideration Obligation InterestonContingentConsiderationObligation	0	USD
CY2017Q4	sgry	Lease Obligation Noncurrent LeaseObligationNoncurrent	121627000	USD
CY2017Q4	sgry	Long Term Tax Receivable Agreement Liability LongTermTaxReceivableAgreementLiability	44300000	USD
CY2017Q4	sgry	Medical Malpractice Liability Noncurrent MedicalMalpracticeLiabilityNoncurrent	16450000	USD
	sgry	Non Controlling Interest Acquisitions And Disposals Of Interests Held By Non Controlling Interest Holders Net NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet	19401000	USD
	sgry	Noncash Gain Loss Related To Litigation Settlement NoncashGainLossRelatedToLitigationSettlement	8740000	USD
	sgry	Noncontrolling Interests Decrease From Reallocation Due To Pushdown Accounting NoncontrollingInterestsDecreaseFromReallocationDueToPushdownAccounting	21248000	USD
CY2017Q4	sgry	Number Of Surgical Facilities Owned NumberOfSurgicalFacilitiesOwned	124	surgical_facility
CY2017Q4	sgry	Numberof Surgical Facilities Owned Consolidated NumberofSurgicalFacilitiesOwnedConsolidated	108	surgical_facility
CY2017Q4	sgry	Numberof Surgical Facilities Owned Majority Interest NumberofSurgicalFacilitiesOwnedMajorityInterest	84	surgical_facility
	sgry	Terminationof Management Agreementand Ipo Costs TerminationofManagementAgreementandIPOCosts	0	USD
CY2017Q4	sgry	Third Party Settlements Payable Current ThirdPartySettlementsPayableCurrent	1000000	USD
CY2017Q4	sgry	Optical Products Receivable OpticalProductsReceivable	7563000	USD
	sgry	Proceeds From Payments For Financing Lease Obligation ProceedsFromPaymentsForFinancingLeaseObligation	1007000	USD
	sgry	Redeemable Noncontrolling Interest Decrease From Distributions To Noncontrolling Interest Holders RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	8228000	USD
	sgry	Redeemable Noncontrolling Interest Increase Decrease From Redemptions Or Purchase Of Interests RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests	819000	USD
	sgry	Redeemable Noncontrolling Interest Reallocation Due To Pushdown Accounting RedeemableNoncontrollingInterestReallocationDueToPushdownAccounting	21248000	USD
	sgry	Related Party Transaction Annual Management Fee Paidper Agreement RelatedPartyTransactionAnnualManagementFeePaidperAgreement	0	USD
CY2017	sgry	Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Deferred Tax Asset Provisional Income Tax Expense TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalIncomeTaxExpense	64000000	USD
CY2017Q4	sgry	Tax Receivable Agreement Liability Noncurrent TaxReceivableAgreementLiabilityNoncurrent	43791000	USD
	sgry	Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Deferred Tax Liability Provisional Income Tax Benefit TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityProvisionalIncomeTaxBenefit	25300000	USD
	sgry	Tax Receivable Agreement Expense Benefit TaxReceivableAgreementExpenseBenefit	-25329000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	288023000	USD
CY2017Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	9873000	USD
	sgry	Undistributed Earnings Loss Allocatedto Participating Securities Including Dividends Accrued UndistributedEarningsLossAllocatedtoParticipatingSecuritiesIncludingDividendsAccrued	10481000	USD
CY2017Q4	sgry	Variable Interest Entity Numberof Facilities VariableInterestEntityNumberofFacilities	3	Practice
CY2017Q4	sgry	Variable Interest Entity Numberof Facilities VariableInterestEntityNumberofFacilities	3	Anesthesia_Practice
CY2017Q4	sgry	Variable Interest Entity Numberof Facilities VariableInterestEntityNumberofFacilities	5	surgical_facility
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	84710000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Excluding Capital Leased Assets AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets	86387000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Excluding Capital Leased Assets AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets	19680000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	695560000	USD
	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	10481000	USD
	us-gaap	Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock	15566000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1887000	USD
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2026000	USD
CY2017Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	10429000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	-559000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1800000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1822000	USD
CY2017Q4	us-gaap	Assets Assets	4622773000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	563225000	USD
	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	7470000	USD
CY2017Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	27594000	USD
CY2017Q4	us-gaap	Capital Leases Balance Sheet Assets By Major Class Net CapitalLeasesBalanceSheetAssetsByMajorClassNet	16200000	USD
CY2017Q4	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	33314000	USD
CY2017Q4	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	9100000	USD
CY2017Q4	us-gaap	Capital Leases Future Minimum Payments Due In Five Years CapitalLeasesFutureMinimumPaymentsDueInFiveYears	1986000	USD
CY2017Q4	us-gaap	Capital Leases Future Minimum Payments Due In Four Years CapitalLeasesFutureMinimumPaymentsDueInFourYears	3505000	USD
CY2017Q4	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	5020000	USD
CY2017Q4	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	7404000	USD
CY2017Q4	us-gaap	Capital Leases Future Minimum Payments Due Thereafter CapitalLeasesFutureMinimumPaymentsDueThereafter	6299000	USD
CY2017Q4	us-gaap	Capital Leases Future Minimum Payments Interest Included In Payments CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments	5720000	USD
CY2017Q4	us-gaap	Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments	27594000	USD
CY2017Q4	us-gaap	Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation	5800000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	174914000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	214206000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-39292000	USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48687136	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48687136	shares
CY2017Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	487000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-41316000	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	39634000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-1682000	USD
CY2017Q3	us-gaap	Cost Of Revenue CostOfRevenue	102924000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	441628000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Deferred Expense DeferredTaxLiabilitiesDeferredExpense	717000	USD
CY2017Q4	us-gaap	Cost Of Revenue CostOfRevenue	338704000	USD
	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-111000	USD
	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	990000	USD
CY2017Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	0	USD
	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	77472000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	71031000	USD
CY2017Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	28380000	USD
CY2017Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	65100000	USD
	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-6712000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	3024000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	171731000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	132319000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	132319000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	160699000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	137794000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4961000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	0	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	2545000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Contingencies DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies	3236000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	0	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11032000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11000000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Deferred Financing Costs DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts	0	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	12441000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	725000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	12098000	USD
CY2017Q4	us-gaap	Deferred Taxes Business Combination Valuation Allowance Allocated To Contributed Capital DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital	1800000	USD
CY2017Q4	us-gaap	Deferred Taxes Business Combination Valuation Allowance Available To Reduce Goodwill DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceGoodwill	300000	USD
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2300000	USD
	us-gaap	Depreciation Depreciation	20000000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	21804000	USD
CY2017Q4	us-gaap	Disposal Group Including Discontinued Operation Consideration DisposalGroupIncludingDiscontinuedOperationConsideration	1300000	USD
CY2017Q4	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	3900000	USD
CY2017Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.57
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.39
CY2017Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.83
CY2017Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.57
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.39
CY2017Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.83
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.24
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	49625000	USD
CY2017Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	6600000	USD
CY2017Q4	us-gaap	Estimated Insurance Recoveries EstimatedInsuranceRecoveries	12800000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2000000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	26034000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	4966000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	2874000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	3730000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	4172000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	4576000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	48352000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	46352000	USD
	us-gaap	Finite Lived Intangible Assets Purchase Accounting Adjustments FiniteLivedIntangibleAssetsPurchaseAccountingAdjustments	3873000	USD
	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	474000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-5000	USD
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	800000	USD
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	8740000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	29153000	USD
CY2017Q4	us-gaap	Goodwill Goodwill	3346838000	USD
CY2017Q3	us-gaap	Goodwill Goodwill	3269225000	USD
	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	49317000	USD
CY2017Q4	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	30253000	USD
	us-gaap	Goodwill Written Off Related To Sale Of Business Unit GoodwillWrittenOffRelatedToSaleOfBusinessUnit	1957000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	69957000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	3319000	USD
	us-gaap	Income Loss From Equity Method Investments Net Of Dividends Or Distributions IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions	-678000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	71639000	USD
	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	529000	USD
	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	64343000	USD
	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	24485000	USD
	us-gaap	Income Tax Reconciliation Minority Interest Income Expense IncomeTaxReconciliationMinorityInterestIncomeExpense	13872000	USD
	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	306000	USD
	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	129000	USD
	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	0	USD
	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	1685000	USD
	us-gaap	Income Tax Reconciliation Tax Contingencies Other IncomeTaxReconciliationTaxContingenciesOther	-191000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	485000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	31500000	USD
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-14494000	USD
CY2017Q4	us-gaap	Insurance Receivable For Malpractice Current InsuranceReceivableForMalpracticeCurrent	2828000	USD
CY2017Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	60908000	USD
CY2017Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	58908000	USD
CY2017Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	56750000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-48740000	USD
	us-gaap	Interest Paid Net InterestPaidNet	40872000	USD
CY2017Q4	us-gaap	Interest Payable Current InterestPayableCurrent	20537000	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	44951000	USD
CY2017Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	74282000	USD
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	175403000	USD
CY2017	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	27800000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4622773000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	303005000	USD
CY2017Q4	us-gaap	Long Term Accounts Notes And Loans Receivable Net Noncurrent LongTermAccountsNotesAndLoansReceivableNetNoncurrent	2263000	USD
CY2017Q4	us-gaap	Long Term Debt LongTermDebt	2186291000	USD
CY2017Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	2130556000	USD
CY2017Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	58726000	USD
CY2017Q4	us-gaap	Long Term Debt And Capital Lease Obligations Including Current Maturities LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities	2189282000	USD
CY2017Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	393597000	USD
CY2017Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	58726000	USD
CY2017Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	8110000	USD
CY2017Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	411748000	USD
CY2017Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	1277253000	USD
CY2017Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	36857000	USD
CY2017Q4	us-gaap	Minority Interest MinorityInterest	681879000	USD
	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	25262000	USD
	us-gaap	Minority Interest Decrease From Redemptions MinorityInterestDecreaseFromRedemptions	1545000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-53624000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-38893000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	53225000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-9140000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-41316000	USD
CY2017Q4	us-gaap	Net Income Loss NetIncomeLoss	-32176000	USD
CY2017Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	6492000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	39634000	USD
CY2017Q4	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	33142000	USD
	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	12931000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-67363000	USD
	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	-14613000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	14872000	USD
CY2017	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3	segment
CY2017Q4	us-gaap	Number Of States In Which Entity Operates NumberOfStatesInWhichEntityOperates	32	state
CY2017Q4	us-gaap	Off Market Lease Unfavorable OffMarketLeaseUnfavorable	11889000	USD
	us-gaap	Operating Expenses OperatingExpenses	500334000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	92270000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	564716000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	67513000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	52582000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	56558000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	62735000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	67136000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	258192000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Receivable OperatingLeasesFutureMinimumPaymentsReceivable	4200000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	27868000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	52717000	USD
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	1316000	USD
CY2017Q4	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	9123000	USD
	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	-25329000	USD
CY2017Q4	us-gaap	Payables To Customers PayablesToCustomers	18096000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2009000	USD
	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	0	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	4000	USD
	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	33490000	USD
CY2017Q4	us-gaap	Other Assets Current OtherAssetsCurrent	24302000	USD
CY2017Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	13318000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	48350000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	32281000	USD
CY2017Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	109944000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	178689000	USD
	us-gaap	Other Nonrecurring Income Expense OtherNonrecurringIncomeExpense	0	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	29249000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10827000	USD
CY2017	us-gaap	Preferred Stock Amount Of Preferred Dividends In Arrears PreferredStockAmountOfPreferredDividendsInArrears	9200000	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2017	us-gaap	Preferred Stock Per Share Amounts Of Preferred Dividends In Arrears PreferredStockPerShareAmountsOfPreferredDividendsInArrears	29.56
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	55337000	USD
CY2017Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	16835000	USD
	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	1183000	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	409000	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-590000	USD
	us-gaap	Proceeds From Payments To Minority Shareholders ProceedsFromPaymentsToMinorityShareholders	998000	USD
	us-gaap	Professional Fees ProfessionalFees	45061000	USD
CY2017Q3	us-gaap	Profit Loss ProfitLoss	-2648000	USD
	us-gaap	Profit Loss ProfitLoss	-1682000	USD
CY2017Q4	us-gaap	Profit Loss ProfitLoss	966000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross Excluding Capital Leased Assets PropertyPlantAndEquipmentGrossExcludingCapitalLeasedAssets	290640000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross Excluding Capital Leased Assets PropertyPlantAndEquipmentGrossExcludingCapitalLeasedAssets	418216000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net Excluding Capital Leased Assets PropertyPlantAndEquipmentNetExcludingCapitalLeasedAssets	204253000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net Excluding Capital Leased Assets PropertyPlantAndEquipmentNetExcludingCapitalLeasedAssets	398536000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	12455000	USD
CY2017Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	299316000	USD
CY2017Q3	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	271001000	USD
CY2017Q4	us-gaap	Redeemable Noncontrolling Interest Equity Preferred Redemption Value RedeemableNoncontrollingInterestEquityPreferredRedemptionValue	330806000	USD
CY2017Q4	us-gaap	Revenues Revenues	460346000	USD
CY2017Q4	us-gaap	Self Insurance Reserve SelfInsuranceReserve	21000000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1887000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	18629000	USD
CY2017Q4	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	315000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-41316000	USD
CY2017Q3	us-gaap	Revenues Revenues	132258000	USD
	us-gaap	Revenues Revenues	592604000	USD
CY2017Q4	us-gaap	Security Deposit SecurityDeposit	3151000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12687	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	7058	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12687	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	20.10
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	20.10
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y6M
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y1M28D
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	585000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	0	USD
CY2017Q4	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	50000000	USD
CY2017Q4	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	48000000	USD
	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	2009000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	654731000	USD
CY2017Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1336610000	USD
CY2017Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1405086000	USD
	us-gaap	Supplies Expense SuppliesExpense	161015000	USD
CY2017Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	4912000	USD
	us-gaap	Temporary Equity Accretion Of Dividends TemporaryEquityAccretionOfDividends	10481000	USD
	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	15566000	USD
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	15566000	USD
CY2017Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	330806000	USD
CY2017Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	310000000	USD
	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	5241000	USD
CY2017Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	310000	shares
CY2017Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	310000	shares
CY2017Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	310000	shares
CY2017Q4	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	11.12
CY2017Q4	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	180664	shares
	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	26047000	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1061000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	690000	USD
CY2017	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	407000	USD
CY2017	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	100000	USD
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Acquisition UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition	36000	USD
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	200000	USD
CY2017	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	3600000	USD
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48319193	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48319193	shares
CY2017	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Reclassifications</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Certain reclassifications have been made to the comparative periods' financial statements to conform to the current year presentation. </font></div></div>
CY2017	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Organization</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">Surgery Partners, Inc.,</font><font style="font-family:inherit;font-size:10pt;"> a </font><font style="font-family:inherit;font-size:9pt;">Delaware corporation (together with its subsidiaries, the “Company”), was formed April 2, 2015, as a holding company for the purpose of facilitating an initial public offering (the “IPO”) of shares of common stock. Prior to September 30, 2015, the Company conducted business through Surgery Center Holdings, Inc. and its subsidiaries. Surgery Center Holdings, LLC was and is the sole indirect owner of the equity interests of Surgery Center Holdings, Inc. and had no other material assets. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">On September 30, 2015, Surgery Partners, Inc. became the direct parent and sole member of Surgery Center Holdings, LLC (the "Reorganization"). In the Reorganization, all of the equity interests held by the pre-IPO Owners of Surgery Center Holdings, LLC were contributed to Surgery Partners, Inc. in exchange for </font><font style="font-family:inherit;font-size:9pt;">33,871,990</font><font style="font-family:inherit;font-size:9pt;"> shares of common stock of Surgery Partners, Inc. and certain rights to additional payments under a tax receivable agreement. After giving effect to the Reorganization, Surgery Partners, Inc. is a holding company, and its sole material asset is an equity interest in Surgery Center Holdings, LLC. The Company's consolidated financial statements for periods prior to the Reorganization represent the historical operating results and financial position of Surgery Center Holdings, Inc. and certain of its subsidiaries.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">On </font><font style="font-family:inherit;font-size:9pt;">October 1, 2015</font><font style="font-family:inherit;font-size:9pt;">, the Company completed its IPO of </font><font style="font-family:inherit;font-size:9pt;">14,285,000</font><font style="font-family:inherit;font-size:9pt;"> shares of common stock at an offering price of </font><font style="font-family:inherit;font-size:9pt;">$19.00</font><font style="font-family:inherit;font-size:9pt;"> per share. On </font><font style="font-family:inherit;font-size:9pt;">October 6, 2015</font><font style="font-family:inherit;font-size:9pt;">, the Company received net proceeds from the sale of common stock in this offering of </font><font style="font-family:inherit;font-size:9pt;">$255.8 million</font><font style="font-family:inherit;font-size:9pt;">, after deducting underwriting discounts and other fees of </font><font style="font-family:inherit;font-size:9pt;">$15.6 million</font><font style="font-family:inherit;font-size:9pt;">. These net proceeds were used to repay a portion of the borrowings outstanding under the 2014 Second Lien and to pay fees associated with this offering. The Company also incurred an additional </font><font style="font-family:inherit;font-size:9pt;">$4.8 million</font><font style="font-family:inherit;font-size:9pt;"> in costs directly related to the IPO.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">On August 31, 2017, the Company completed its acquisition of NSH Holdco, Inc. (“NSH”). Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 9, 2017, by and among the Company, SP Merger Sub, Inc., a wholly owned subsidiary of the Company, NSH, and IPC / NSH, L.P. (solely in its capacity as sellers’ representative), as amended by that certain Letter Amendment, dated as of July 7, 2017 (as amended, the “NSH Merger Agreement”), SP Merger Sub, Inc. merged with and into NSH with NSH continuing as the surviving corporation and a wholly owned subsidiary of Surgery Center Holdings, Inc. (the “NSH Merger”). Also on August 31, 2017, (i) the Company completed the sale and issuance of </font><font style="font-family:inherit;font-size:9pt;">310,000</font><font style="font-family:inherit;font-size:9pt;"> shares of the Company's preferred stock, par value </font><font style="font-family:inherit;font-size:9pt;">$0.01</font><font style="font-family:inherit;font-size:9pt;"> per share, designated as </font><font style="font-family:inherit;font-size:9pt;">10.00%</font><font style="font-family:inherit;font-size:9pt;"> Series A Convertible Perpetual Participating Preferred Stock (the “Series A Preferred Stock”) to BCPE Seminole Holdings LP (“Bain”), a fund advised by an affiliate of Bain Capital Private Equity, at a purchase price of </font><font style="font-family:inherit;font-size:9pt;">$1,000</font><font style="font-family:inherit;font-size:9pt;"> per share in cash (the “Preferred Private Placement”) pursuant to the Securities Purchase Agreement, dated as of May 9, 2017, by and between the Company and Bain (the “Preferred Stock Purchase Agreement”), and (ii) Bain completed its purchase of </font><font style="font-family:inherit;font-size:9pt;">26,455,651</font><font style="font-family:inherit;font-size:9pt;"> shares (the “Purchased Shares”) of the Company's common stock, par value </font><font style="font-family:inherit;font-size:9pt;">$0.01</font><font style="font-family:inherit;font-size:9pt;"> per share (the “Common Stock”) from H.I.G. Surgery Centers, LLC (“H.I.G.”) at a purchase price of </font><font style="font-family:inherit;font-size:9pt;">$19.00</font><font style="font-family:inherit;font-size:9pt;"> per share in cash (the “Private Sale”) pursuant to the Stock Purchase Agreement, dated as of May 9, 2017, by and among the Company, Bain, H.I.G. and H.I.G. Bayside Debt & LBO Fund II L.P. (for the purposes stated therein) (the “Common Stock Purchase Agreement” and together with the NSH Merger Agreement, the Preferred Stock Purchase Agreement and the other agreements and documents executed in connection therewith, including the TRA (as defined in Note 2. “Significant Accounting Policies - Income Taxes and Tax Receivable Agreement”), the “Transaction Agreements”). As of August 31, 2017, the Purchased Shares represented approximately </font><font style="font-family:inherit;font-size:9pt;">54.2%</font><font style="font-family:inherit;font-size:9pt;"> of the Company’s outstanding Common Stock. As a result of the Preferred Private Placement and the Private Sale, Bain became the controlling stockholder of the Company, holding Series A Preferred Stock and Common Stock that collectively represent approximately </font><font style="font-family:inherit;font-size:9pt;">65.7%</font><font style="font-family:inherit;font-size:9pt;"> of the voting power of all classes of capital stock of the Company as of August 31, 2017, and H.I.G. and its affiliated investment funds no longer own any capital stock of the Company.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">In connection with the change of control effected by the Preferred Private Placement and the Private Sale, the Company elected to apply “pushdown” accounting by applying the guidance in Accounting Standards Codification Topic ("ASC") 805, </font><font style="font-family:inherit;font-size:9pt;font-style:italic;">Business Combinations</font><font style="font-family:inherit;font-size:9pt;">, including the recognition of the Company’s assets and liabilities at fair value as of August 31, 2017, and similarly recognizing goodwill calculated based on the terms of the transaction and the fair value of the new basis of net assets of the Company. Accordingly, the consolidated financial statements of the Company for periods before and after August 31, 2017 reflect different bases of accounting, and the financial positions and results of operations of those periods are not comparable. Throughout the Company's consolidated financial statements and the accompanying notes herein, periods prior to the change of control are identified as "Predecessor" and periods after the change of control are identified as "Successor."</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">As of </font><font style="font-family:inherit;font-size:9pt;">December 31, 2017</font><font style="font-family:inherit;font-size:9pt;"> (Successor), the Company owned and operated a national network of surgical facilities and ancillary services in </font><font style="font-family:inherit;font-size:9pt;">32</font><font style="font-family:inherit;font-size:9pt;"> states. The surgical facilities, which include ambulatory surgery centers ("ASCs") and surgical hospitals, primarily provide non-emergency surgical procedures across many specialties, including, among others, gastroenterology ("GI"), general surgery, ophthalmology, orthopedics and pain management. The Company's surgical hospitals provide services such as diagnostic imaging, laboratory, obstetrics, oncology, pharmacy, physical therapy and wound care. Ancillary services are comprised of a diagnostic laboratory, multi-specialty physician practices, urgent care facilities, anesthesia services and optical services. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> As of </font><font style="font-family:inherit;font-size:9pt;">December 31, 2017</font><font style="font-family:inherit;font-size:9pt;"> (Successor), the Company owned or operated a portfolio of </font><font style="font-family:inherit;font-size:9pt;">124</font><font style="font-family:inherit;font-size:9pt;"> surgical facilities, comprised of </font><font style="font-family:inherit;font-size:9pt;">106</font><font style="font-family:inherit;font-size:9pt;"> ASCs and </font><font style="font-family:inherit;font-size:9pt;">18</font><font style="font-family:inherit;font-size:9pt;"> surgical hospitals. The Company owns these facilities in partnership with physicians and, in some cases, healthcare systems in the markets and communities it serves. The Company owned a majority interest in </font><font style="font-family:inherit;font-size:9pt;">84</font><font style="font-family:inherit;font-size:9pt;"> of the surgical facilities and consolidated </font><font style="font-family:inherit;font-size:9pt;">108</font><font style="font-family:inherit;font-size:9pt;"> of these facilities for financial reporting purposes.</font></div></div>
CY2017	us-gaap	Revenue Recognition Sales Of Services RevenueRecognitionSalesOfServices	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Revenues</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">The Company recognizes revenues in the period in which the services are performed. Patient service revenues and receivables from third-party payors are recorded net of estimated contractual adjustments and allowances, which the Company estimates based on the historical trend of its cash collections and contractual write-offs, accounts receivable agings, established fee schedules, contracts with payors and procedure statistics.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">Other service revenues.</font><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;"> </font><font style="font-family:inherit;font-size:9pt;"> Optical service revenues consist of product sales from the Company's optical laboratories as well as handling charges billed to the members of the Company's optical products purchasing organization. The Company's optical products purchasing organization negotiates volume buying discounts with optical products manufacturers. The buying discounts and any handling charges billed to the members of the buying group represent the revenue recognized for financial reporting purposes. Revenue is recognized as orders are shipped to members. The Company bases its estimates for sales returns and discounts on historical experience and has not experienced significant fluctuations between estimated and actual return activity and discounts given. The Company's optical laboratories manufacture and distribute corrective lenses and eyeglasses to ophthalmologists and optometrists. Revenue is recognized when product is shipped, net of allowance for discounts.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other revenues include management and administrative service fees derived from the non-consolidated facilities that the Company accounts for under the equity method, management of surgical facilities in which it does not own an interest, and management services provided to physician practices for which the Company is not required to provide capital or additional assets. The fees derived from these management arrangements are based on a predetermined percentage of the revenues of each facility or practice and are recognized in the period in which services are rendered.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">Patient service revenues.</font><font style="font-family:inherit;font-size:9pt;">  The fee charged for healthcare procedures performed in surgical facilities varies depending on the type of service provided, but usually includes all charges for usage of an operating room, a recovery room, special equipment, medical supplies, nursing staff and medications. The fee does not normally include professional fees charged by the patient’s surgeon, anesthesiologist or other attending physician, which are billed directly by such physicians to the patient or third-party payor. However, in several surgical facilities, the Company charges for anesthesia services. Ancillary service revenues include fees for patient visits to the Company's physician practices, pharmacy services and diagnostic tests ordered by physicians. Patient service revenues are recognized on the date of service, net of estimated contractual adjustments and discounts from third-party payors, including Medicare and Medicaid. Changes in estimated contractual adjustments and discounts are recorded in the period of change.</font></div></div>
CY2017	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and footnotes. Examples include, but are not limited to, estimates of accounts receivable allowances, professional and general liabilities and the estimate of deferred tax assets or liabilities. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. All adjustments are of a normal, recurring nature. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001638833-18-000004-index-headers.html	Edgar Link	pending
0001638833-18-000004-index.html	Edgar Link	pending
0001638833-18-000004.txt	Edgar Link	pending
0001638833-18-000004-xbrl.zip	Edgar Link	pending
a201710-kfiling.htm	Edgar Link	pending
exhibit1011trawaiveragreem.htm	Edgar Link	pending
exhibit1025employmentagree.htm	Edgar Link	pending
exhibit1027letteramendmen.htm	Edgar Link	pending
exhibit1036amendmentno1tom.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
report.css	Edgar Link	pending
sgry-20171231.xml	Edgar Link	completed
sgry-20171231.xsd	Edgar Link	pending
sgry-20171231_cal.xml	Edgar Link	unprocessable
sgry-20171231_def.xml	Edgar Link	unprocessable
sgry-20171231_lab.xml	Edgar Link	unprocessable
sgry-20171231_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending
stockperformancegraph2017a02.jpg	Edgar Link	pending
ye2017exhibit211.htm	Edgar Link	pending
ye2017exhibit231.htm	Edgar Link	pending
ye2017exhibit311.htm	Edgar Link	pending
ye2017exhibit312.htm	Edgar Link	pending
ye2017exhibit321.htm	Edgar Link	pending
ye2017exhibit322.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SGRY
Surgery Partners, Inc. Stock $sgry

2017 Q4 Form 10-K Financial Statement

#000163883318000004 Filed on March 16, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SGRY Surgery Partners, Inc. Stock $sgry

2017 Q4 Form 10-K Financial Statement

#000163883318000004 Filed on March 16, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SGRY
Surgery Partners, Inc. Stock $sgry